TREE NEWS update: Simcere Pharmaceutical announced that its co-developed Class 1 biologic, culerviveimab injection (brand name Yingmule), has been approved by China’s National Medical Products Administration. It becomes the first domestically developed long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV) in the country. The drug was developed in strategic partnership with Ruiyang (Shandong) Biopharmaceutical.
China’s First Long-Acting RSV Preventive Antibody Approved
AI take
This approval marks a meaningful step for China's biopharma sector, as it introduces a domestically developed alternative in the RSV prevention space, a category that has seen global demand. The strategic partnership behind the drug highlights how collaborative R&D models are becoming central to bringing complex biologics to market. For industry watchers, the focus now shifts to how this product is positioned commercially, including pricing and distribution, and whether it prompts faster regulatory timelines for similar preventive antibodies in the pipeline.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
7m ago
Brazil’s Lula says Bolsonaro leaving country is shameful
8m ago
UK PM Burnham Unveils Housing Crisis Plan With More Social Homes
12m ago
Venezuela’s NABEP Delivers First 1M Barrels of Free Crude to US
21m ago
US stock futures close higher, Nasdaq 100 futures up 1.25%
23m ago
US to Grant Visas to Brazil’s Flavio Bolsonaro and Family, Official Says
26m ago
Bolsonaro campaign chief says no information on his whereabouts